Heron Therapeutics (HRTX) Operating Leases (2019 - 2025)

Heron Therapeutics has reported Operating Leases for 7 years, with the latest figure at $780000.0 in Q3 2025.

• For the quarter ending Q3 2025, Operating Leases rose 49.43% year-over-year to $780000.0; the trailing twelve-month figure through Sep 2025 stood at $780000.0 (up 49.43% YoY), and the FY2023 full-year result was $2.8 million, down 49.08% from the prior year.
• Operating Leases for Q3 2025 stood at $780000.0, down from $1.5 million in the prior quarter.
• The five-year high for Operating Leases was $13.8 million in Q1 2021, with the low at $522000.0 in Q3 2024.
• Historically, Operating Leases has averaged $5.5 million across 5 years, with a median of $4.8 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Leases tumbled 85.24% — and 2025, when it soared 49.43%.
• Heron Therapeutics' Operating Leases stood at $8.0 million in 2021, then sank by 31.23% to $5.5 million in 2022, then slumped by 49.08% to $2.8 million in 2023, then tumbled by 81.36% to $522000.0 in 2024, then soared by 49.43% to $780000.0 in 2025.
• The last three Operating Leases figures came in at $780000.0 (Q3 2025), $1.5 million (Q2 2025), and $522000.0 (Q3 2024), per Business Quant data.